MedTrace Logo

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

NCT01303497 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-03-13

No results posted yet for this study

Summary

Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma

Conditions

  • Angiosarcoma

Interventions

DRUG

Paclitaxel

Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)

DRUG

Bevacizumab

Bevacizumab until progression or inacceptable toxicity : * During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV * After 6 cycles of chemotherapy : 15 mg/kg, IV

Sponsors & Collaborators

  • French Sarcoma Group

    collaborator OTHER

  • Study Group of Bone Tumors

    collaborator OTHER

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Nicolas PENEL, MD, PhD · Centre Oscar Lambret

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-10
Primary Completion
2014-04-30
Completion
2019-01-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01303497 on ClinicalTrials.gov